Verily — a company within Alphabet, Google’s parent group — and NVIDIA have announced a strategic partnership focused on AI in medicine. As part of the collaboration, NVIDIA’s technology will be integrated into Verily’s “Pre” platform, which supports healthcare systems, data science, and regulatory processes.
OpenAI has revealed that more than one million users per week discuss suicidal thoughts or readiness to act on them while chatting with ChatGPT. The company also reported that about 560,000 users weekly may show signs of psychotic or manic behavior during their interactions with the chatbot.
Amazon has announced layoffs affecting up to 30,000 corporate employees, representing around 10% of its office workforce. The cuts, set to begin on Tuesday, will impact departments including HR, Devices & Services, Operations, and Amazon Web Services (AWS).
Innovent Biologics announced that its GLP-1 drug, Mazdutide (6 mg), achieved better results than Novo Nordisk’s Semaglutide (1 mg) in a study involving patients with type 2 diabetes and obesity. In the DREAMS-3 trial, Mazdutide reduced HbA1C by an average of 2.03% compared to 1.84% for Semaglutide, and patients lost 10.29% of body weight versus 6% with Ozempic.
